Despite the immunological defect associated with HIV infection (associated with loss of CD4+ T cells) and the higher prevalence of HBeAg+ status in this group, HBV viraemia can be successfully suppressed in the majority of coinfected patients using conventional TDF-based cART regimens. The gene discussed is CD4; the disease is HIV infectious disease.